Effect of doxazosin gastrointestinal therapeutic system on patients with uncontrolled hypertension: The ASOCIA study

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 2, 2006, Pages 271-276

  De Álvaro, Fernando ^a   Hernández Presa, Miguel Angel ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b PFIZER INC   (United States)

Author keywords

1 adrenergic receptor antagonist; ASOCIA; Blood pressure control; Doxazosin GITS; Hypertension

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ALPHA 1 ADRENERGIC RECEPTOR;

ADD ON THERAPY; ADULT; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; EDEMA; FEMALE; FOLLOW UP; GASTROINTESTINAL THERAPEUTIC SYSTEM; HEADACHE; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; POSITIONAL DIZZINESS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYNCOPE; SYSTOLIC BLOOD PRESSURE; URINE INCONTINENCE; XEROSTOMIA; BLOOD PRESSURE; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIGESTIVE SYSTEM; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; DIGESTIVE SYSTEM; DOXAZOSIN; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC, ALPHA-1; TREATMENT OUTCOME;

EID: 33746456540     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000202562.46420.d9     Document Type: Article

References (34)

1. Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25:305-313.
2. Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med. 2002;162:413-420.
3. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757-764.
4. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-1315.
5. American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. Dallas; American Heart Association:2003.
6. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 Report. JAMA. 2003;289:2560-2571.
7. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
8. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood- pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
9. Zanchetti A, Mancia G. Benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens. 1996;14:809-811.
10. Benetos A, Thomas F, Bean K, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med. 2002;162:577-581.
11. Coca A. Evolucion del control de la hipertension arterial en Espana. Resultados del estudio Controlpress. Hypertension. 2002;19:390-399.
12. Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8:189-192.
13. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003; 21:1011-1053.
14. Fulton B, Wagstaff A, Sorkin E. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995;49:295-320.
15. Black HR, Sollins JS, Garofalo JL. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study. Am J Hypertens. 2000;13:468-474.
16. Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol. 2003;41:866-869.
17. Black H, Keck M, Meredith P, et al. An efficacy and safety study of doxazosin gastrointestinal therapeutic system as combination therapy in hypertensive patients (P-393). Am J Hypertens. 2004;17:178A.
18. Pool JL. Effects of doxazosin on serum lipids: a review of the clinical data and molecular basis for altered lipid metabolism. Am Heart J. 1991;121:251-259.
19. Andersson P, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Am J Hypertens. 1996;9:323-333.
20. Yamada S, Suzuki M, Tanaka C, et al. Comparative study on alpha 1-adrenoceptor antagonist binding in human prostate and aorta. Clin Exp Pharmacol Physiol. 1994;21:405-411.
21. Huupponen R, Lehtonen A, Vahatalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol. 1992;43:365-368.
22. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
23. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203-209.
24. Jansson J, Johansson B, Boman K, et al. Effects of doxazosin and atenolol on the fibrinolytic system in patients with hypertension and elevated serum cholesterol. Eur J Clin Pharmacol. 1991;40:321-326.
25. Chung M, Vashi V, Puente J, et al. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48:678-687.
26. Calvo C, Gil-Extremera B, Gomez-Fernanzez P, et al. Doxazosin GITS versus standard doxazosin in mild to moderate hypertension. Int J Cardiol. 2005;101:I97-I104.
27. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
28. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345:1291-1297.
29. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
30. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328:914-921.
31. Black HR, Elliott WJ, Neaton JD, et al. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension. 2001;37:12-18.
32. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-1762.
33. Campo C, Segura J, Roldan C, et al. Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. Blood Press Suppl. 2003;(suppl 2):16-21.
34. Labios M, Martinez M, Gabriel F, et al. Flow cytometric analysis of platelet activation in hypertensive patients. Effect of doxazosin. Thromb Res. 2003;110:203-208.